黄芪治疗复发性阿弗他溃疡疗效分析及作用机理探讨

Treatment of recurrent aphthous ulcerations by astragali modulating transcription T-bet and GATA-3.

目的:观察黄芪治疗复发性阿弗他溃疡(RAU)的临床疗效,并探讨黄芪对RAU患者失衡表达转录因子T-bet/GATA-3的调节作用。方法:健康对照组25例,RAU患者65例随机分为RAU常规治疗组和黄芪治疗组,观察治疗后1年溃疡复发情况;酶联免疫吸附测定法检测血清中白细胞介素(IL-4)和干扰素-γ(IFN-γ)含量;Westernblot法检测外周血单个核细胞中T-bet和GATA-3蛋白表达。结果:黄芪治疗组总有效率为90.91%,显著高于常规治疗组25%(P<0.01)。血清IL-4含量,对照组(25.45±3.69)pg/ml,显著低于RAU常规治疗组(42.32±4.47)pg/ml,(P<0.01),治疗组(32.35±5.24)pg/ml显著高于对照组(P<0.01)。血清IFN-γ含量,对照组(24.53±2.69)pg/ml显著高于常规治疗组(17.57±0.68)pg/m(lP<0.01),黄芪治疗组(21.60±3.03)pg/ml显著低于对照组(P<0.01),显著高于常规治疗组(P<0.01)。外周血单个核细胞中T-bet蛋白表达,健康对照组(0.75±0.17),显著高于常规治疗组(0.21±0.09)(P<0.01),黄芪治疗组(0.56±0.23),显著高于常规治疗RAU组(P<0.01),显著低于对照组(P<0.01);外周血单个核细胞中GATA-3蛋白表达,健康对照组(1.06±0.20),显著低于常规治疗组(1.82±0.17)(P<0.01),黄芪治疗组(1.04±0.27),显著低于常规治疗组(P<0.01),与对照组比较无统计学差异(P>0.05)。结论:黄芪通过调节转录因子T-bet和GATA-3的平衡表达,纠正RAU患者Th1/Th2细胞亚群失衡的免疫异常,有效治疗RAU溃疡复发。

Objective：To investigate astragali treatment on recurrent aphthous ulcerations, and to explore astragali modulating transcription factor T-bet and GATA-3. Method： Sixty-five recurrent aphthous ulcerations RAU were randomly divided into the routine treatment group （32cases） and the astragali treatment group （33cases）. The clinical effects of the two groups was estimated. The concentrations of interferon-γ（IFN-γ） and interleukin-4 （IL-4） in the serum were determined by enzyme-linked immunosorbent assay （ELISA）.Expression of T-bet and GATA-3 proteins in the PBMCs were detected by Western blot. Result：The effective rate of the astragali treatment group and the routine treatment group were 90.91% and 25% respectively, which had statistical significance （P〈0.01）. The concentrations of IL-4 in the serum were （25.45±3.69） pg/ml in the control group, and （42.32±4.74） pg/ml in the RAU routine treatment group （p〈0.01）,The concentrations of IL-4 in the of the astragali treatment group, serum were （32.35±5.24） pg / ml, which decreased compared with those of the RAU routine treatment group （P〈0.01） and increased compared with those of the control group（P〈0.01）. The concentration of intederon-γ in the serum of the control group was （24.53±2.69） pg / ml,which was significantly elevated compared with those of the RAU routine treatment group （17.57±0.68） pg/ml （P〈0.01）. The concentration of interferon-γ in the serum of the astragali treatment group was （21.60±3.03） pg / ml, which increased compared with those of the RAU routine treatment group （P〈0.01） and decreased compared with those of the control group （P〈0.01）.The expression of T-bet protien were （0.75±0.17） in the control group, and （0.21±0.09） in the RAU routine treatment group（p〈0.01）. The expression of T-bet protien was （0.56±0.23）in the astragali treatment group which increased compared with those of the RAU routine treatment group（P〈0.01）and decreased compared with those of the control group （P〈0.01）.The level of GATA-3 protein was （1.06±0.20）in the control group,and（0.21±0.09） in the RAU routine treatment group （P〈0.01）. In the astragali treatment group,The level of GATA-3 protein was （1.04±0.27）, which significantly decreased compared with those of the RAU routine treatment group （P〈0.01） .There was no difference in the levels of GATA-3 protein between the astragali treatment group and the control group（P〉0.05）. Conclusion： We concluded that astragali treated RAU by modulating key master switches GATA-3 and Tbet.